187 related articles for article (PubMed ID: 22213159)
1. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
2. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
3. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
4. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
[TBL] [Abstract][Full Text] [Related]
5. A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth.
Huang W; Fridman Y; Bonfil RD; Ustach CV; Conley-LaComb MK; Wiesner C; Saliganan A; Cher ML; Kim HR
Oncogene; 2012 Oct; 31(42):4527-35. PubMed ID: 22158043
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Zhang S; Gera L; Mamouni K; Li X; Chen Z; Kucuk O; Wu D
Oncotarget; 2016 May; 7(19):27489-98. PubMed ID: 27050371
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
Kong D; Banerjee S; Huang W; Li Y; Wang Z; Kim HR; Sarkar FH
Cancer Res; 2008 Mar; 68(6):1927-34. PubMed ID: 18339874
[TBL] [Abstract][Full Text] [Related]
8. Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.
Chen Y; Gera L; Zhang S; Li X; Yang Y; Mamouni K; Wu AY; Liu H; Kucuk O; Wu D
Cancer Lett; 2019 Apr; 446():62-72. PubMed ID: 30660650
[TBL] [Abstract][Full Text] [Related]
9. Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Momeny M; Sankanian G; Hamzehlou S; Yousefi H; Esmaeili F; Alishahi Z; Karimi B; Zandi Z; Shamsaiegahkani S; Sabourinejad Z; Kashani B; Nasrollahzadeh A; Mousavipak SH; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2020 Sep; 882():173298. PubMed ID: 32593665
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
11. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
Xu L; Tong R; Cochran DM; Jain RK
Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
[TBL] [Abstract][Full Text] [Related]
12. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.
Yin JJ; Zhang L; Munasinghe J; Linnoila RI; Kelly K
Cancer Res; 2010 Nov; 70(21):8662-73. PubMed ID: 20959486
[TBL] [Abstract][Full Text] [Related]
13. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
[TBL] [Abstract][Full Text] [Related]
14. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
[TBL] [Abstract][Full Text] [Related]
15. PDGF-D signaling: a novel target in cancer therapy.
Wang Z; Kong D; Li Y; Sarkar FH
Curr Drug Targets; 2009 Jan; 10(1):38-41. PubMed ID: 19149534
[TBL] [Abstract][Full Text] [Related]
16. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
18. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Koreckij T; Nguyen H; Brown LG; Yu EY; Vessella RL; Corey E
Br J Cancer; 2009 Jul; 101(2):263-8. PubMed ID: 19603032
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
Kendrew J; Odedra R; Logié A; Taylor PJ; Pearsall S; Ogilvie DJ; Wedge SR; Jürgensmeier JM
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1021-32. PubMed ID: 23355042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
